Sei Investments Co. Acquires 1,755 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

Sei Investments Co. boosted its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,304 shares of the company’s stock after purchasing an additional 1,755 shares during the quarter. Sei Investments Co.’s holdings in Schrödinger were worth $392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SDGR. Nikko Asset Management Americas Inc. boosted its position in shares of Schrödinger by 108.7% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,464,911 shares of the company’s stock valued at $47,499,000 after acquiring an additional 1,283,949 shares during the period. Monaco Asset Management SAM bought a new stake in Schrödinger in the 4th quarter valued at $1,543,000. Swiss National Bank grew its position in Schrödinger by 1.2% in the 4th quarter. Swiss National Bank now owns 125,100 shares of the company’s stock worth $2,413,000 after purchasing an additional 1,500 shares during the last quarter. Amundi increased its holdings in shares of Schrödinger by 197.7% during the 4th quarter. Amundi now owns 26,753 shares of the company’s stock worth $544,000 after purchasing an additional 17,766 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Schrödinger during the fourth quarter valued at about $325,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Trading Down 1.5 %

NASDAQ SDGR opened at $19.22 on Friday. Schrödinger, Inc. has a 1-year low of $16.60 and a 1-year high of $28.47. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -8.21 and a beta of 1.77. The stock’s 50 day moving average is $21.99 and its two-hundred day moving average is $20.70.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The company had revenue of $88.32 million during the quarter, compared to analyst estimates of $83.20 million. On average, analysts predict that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total value of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at $599,357.44. The trade was a 16.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SDGR. KeyCorp lifted their target price on Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Piper Sandler decreased their price objective on Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $32.29.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.